The strong Q4 beat combined with FY2027 guidance above the long-term target and a massive $5.0B buyback authorization creates a powerful catalyst. Traders should watch for upward analyst revisions and potential multiple expansion as the market prices in sustained double-digit EPS growth. The Kroger contract renewal removes a key overhang.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 11 $240.26entry
- T+1 · 3mo ago −2.54%α −2.79% · $234.16
- T+5 · 3mo ago −2.20%α −1.79% · $234.98
- T+20 · 2mo ago −0.14%α +0.92% · $239.92
- T+60 · 13d ago +9.02%α +9.51% · $261.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cardinal Health reported strong Q4 FY2026 results with revenue of $63.7B (+6% YoY) and GAAP EPS of $1.70 (+70% YoY). Non-GAAP EPS of $2.91 (+40% YoY) included a $0.31 one-time benefit from IEEPA tariff refunds; excluding that, non-GAAP EPS grew 25% to $2.60. The company provided FY2027 non-GAAP EPS guidance of $12.40-$12.60 (+13-15% growth), above its long-term target, and announced a $5.0B incremental share repurchase authorization. The combination of a strong Q4 beat, raised FY2027 guidance above consensus, and a massive capital return program is a clear bullish signal for the stock.
Key Financial Metrics
Key Facts
- Q4 FY2026 revenue $63.7B (+6% YoY), GAAP EPS $1.70 (+70% YoY), Non-GAAP EPS $2.91 (+40% YoY)
- FY2027 non-GAAP EPS guidance $12.40-$12.60 (+13-15% growth), above long-term target
- Board approved $5.0B incremental share repurchase authorization, total authorization now $6.4B
- FY2026 operating cash flow $5.2B, adjusted free cash flow $5.0B
- All five operating segments grew profit double-digits in FY2026
- Pharmaceutical & Specialty Solutions segment profit +21% in Q4
- GMPD segment profit $150M in Q4, driven by $100M IEEPA tariff refunds
- Other segment (NPHS, at-Home, OptiFreight) profit +14% in Q4
- Completed $1.4B in share repurchases in FY2026, including $350M incremental ASR
- Long-term renewal of wholesaler distribution contract with Kroger
Financial Impact
FY2027 non-GAAP EPS guidance of $12.40-$12.60 represents 13-15% growth over adjusted FY2026 non-GAAP EPS of $10.95, above the company's long-term EPS growth target. $5.0B incremental buyback authorization signals strong capital return.
Risk Factors
- GMPD segment profit excluding IEEPA tariff refunds declined 29% in Q4, indicating underlying weakness
- Tariff uncertainty remains a risk for the medical products segment
- Interest expense increased 7% in Q4 and is guided higher for FY2027 ($240M-$290M)
- Integration of recent acquisitions (Strive Medical, AdaptHealth diabetes business) carries execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000721371-26-000037 |
| Document: cah-20260811.htm | 0000721371-26-000037 |
| Document: 0000721371-26-000037-index-headers.html | 0000721371-26-000037 |
| Document: 0000721371-26-000037-index.html | 0000721371-26-000037 |
| Document: 0000721371-26-000037.txt | 0000721371-26-000037 |
| 8-K Data (Synthetic) | 0000721371-26-000037 |
Track record
17 reports on CAH
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 3 Neutral 2/10 Entry $283.50 Now $283.85 +0.12% settles Nov 24
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $283.35 Now $283.85 −0.18% settles Nov 23
- Nov 11, 20265d ago Press Release Neutral 2/10 Entry $278.14 Now $283.85 +2.05% settles Nov 19
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $267.82 to $278.14 Now $283.85 +5.99% ▲ +3.85% +0.56% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $251.09 to $267.82 Now $283.85 +13.05% ▲ +6.66% +11.39% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $244.76 to $261.93 Now $283.85 +15.97% ▲ +7.01% +7.73% vs SPY
- Oct 27, 202621d ago GOVT-CONTRACT Neutral 4/10 Entry $244.76 to $261.93 Now $283.85 +15.97% ▲ +7.01% +7.73% vs SPY
- Oct 1, 20266w ago 8-K Neutral 5/10 Entry $230.09 to $238.96 Now $283.85 +23.36% ▲ +3.85% +2.55% vs SPY
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $230.09 to $238.96 Now $283.85 +23.36% ▲ +3.85% +2.55% vs SPY
- Aug 20, 202612w ago Insider Cluster Neutral 4/10 Entry $228.46 to $235.13 Now $283.85 +24.24% ▲ +2.92% +1.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers